Drug News

Global Paracetamol Market Set to Grow by $791.9 Million From 2022 to 2027, 

The global Paracetamol market is poised for significant growth, with Technavio Research projecting a substantial increase of USD 791.9 million from 2022 to 2027, showcasing a compound annual growth rate (CAGR) of 8.78% during this forecast period. This growth is further accentuated by North America, which accounts for an impressive 37% of the global market expansion. The dominance of North America in the market is attributed to the United States and Canada, both contributing significantly to the revenue surge. The primary driving force behind this growth is the escalating demand for Paracetamol as an active pharmaceutical ingredient (API), particularly in the production of over-the-counter (OTC) drugs, specifically analgesics and antipyretics.

The market segmentation includes categories such as application (surgical and non-surgical), formulation (powder and granules), and geography (North America, Europe, Asia, and the Rest of the World). Among these, North America stands out as a key player, driving growth and contributing to the market’s overall robust performance.

Key players in the Paracetamol market include Anhui Fubore Pharmaceutical And Chemical Co. Ltd., Anqiu Luan Pharmaceutical Co. Ltd., ATABAY KIMYA SANAYI TICARET AS, Biological E. Ltd., Cipla Ltd., GlaxoSmithKline Plc, Granules India Ltd., Mallinckrodt Plc, Sanofi SA, SEQENS GROUP, Sri Krishna Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Trugen Pharmaceuticals Pvt Ltd., Zhejiang Kangle Pharmaceutical Co. Ltd., and Zhengzhou Sino Chemical Co. Ltd.

Among these, Anhui Fubore Pharmaceutical And Chemical Co. Ltd. stands out for its involvement in the manufacturing of Paracetamol, glucuronolactone, acetylacetone, and pyrazolone.

The segmentation analysis reveals a significant market share growth in the surgical segment during the forecast period, particularly in the perioperative application of Paracetamol for pain management in surgical patients.

The driving force behind the market growth is the rising prevalence of chronic conditions and prescription drug use. The healthcare sector’s continuous expansion is fueled by the increasing prevalence of chronic diseases and the popularity of pain relievers. The World Health Organization reports a staggering 3.55 billion people globally suffering from oral diseases, causing pain and suffering, contributing to the demand for Paracetamol.

Paracetamol’s role as an analgesic and antipyretic for pain relief and fever reduction, both in pediatric and adult dosages, solidifies its position as a staple in over-the-counter (OTC) pharmaceuticals. Its demand, both in generic and brand-name forms, underscores its significance in consumer healthcare and the broader drug industry. Continuous research and development (R&D) contribute to ongoing improvements in pharmaceutical manufacturing and regulatory compliance, further fueling market growth.

The report provides a thorough analysis of the competitive landscape, offering insights into various companies in the market. It covers essential data such as the market’s compound annual growth rate (CAGR), factors driving market growth, precise market size estimation, upcoming trends, changes in consumer behavior, market growth across different regions, and challenges faced by market players.

In summary, the Paracetamol market is experiencing substantial growth, driven by factors such as increased demand for pain relievers, prevalence of chronic diseases, and ongoing research and development efforts in the pharmaceutical industry. North America, led by the United States and Canada, plays a pivotal role in this growth, contributing significantly to the overall revenue surge.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker